A multidrug regimen containing brentuximab vedotin (BV, Adcetris) proved feasible for older patients with advanced classical ...

The dynamics of the cutaneous T-cell lymphoma market are anticipated to change owing to the improvement in research and development activities, increasing prevalence, and the rising geriatric ...

Researchers sought to determine whether SOC pola-R-CHP frontline therapy would be safe and effective in a real-world population of patients with treatment-naïve DLBCL.

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage oncology company leveraging its proprietary RADR® artificial intelligence (AI) platform to systematically transform drug discovery paradigms, today ...

U.S. Market Leads with 74% Share in 2023 Valued at USD 2.71 Billion, Driven by Biotech Innovation, Favorable FDA Approvals, and Rising Chronic Disease Incidence.Austin, July 18, 2025 (GLOBE NEWSWIRE) ...

Roche and Genentech were unable to sufficiently demonstrate the benefit of using Columvi in an earlier treatment setting for ...

Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

Lyell Immunopharma's LYL314 CAR-T therapy shows durable responses in advanced LBCL patients. Learn about trials and upcoming ...

An NHS doctor has said she was concerned that a former nurse-turned-conspiracy theorist influenced her daughter’s refusal of ...

Researchers recommend that details on prescription medications received in the year before diagnosis and treatment initiation be included in clinical trials as essential baseline information.

A novel prediction model estimated 2-year PFS for adults with early-stage classic Hodgkin lymphoma based on four “readily ...

A large-scale national study of primary central nervous system lymphoma (PCNSL) in England has revealed stark differences in ...